Clinical Trials Logo

Filter by:
NCT ID: NCT05389449 Active, not recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Start date: October 28, 2022
Phase: Phase 3
Study type: Interventional

This is a single-arm long-term extension study that will enroll participants with PNH who have completed participation in Alexion-sponsored clinical studies with danicopan as an add on therapy to a C5i.

NCT ID: NCT05389267 Active, not recruiting - Glaucoma Clinical Trials

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

Start date: July 5, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The study purpose is to evaluate the safety of T4090.

NCT ID: NCT05388981 Active, not recruiting - Safety Clinical Trials

Study of Single Doses of SBT115301 in Healthy Participants

Start date: July 25, 2022
Phase: Phase 1
Study type: Interventional

This study will test the safety and effects of SBT115301 when given as a single dose to healthy adult volunteers. It is the first study being done in humans. Increasing dose levels will be given after the safety at lower dose levels is shown. Some participants will receive placebo, and neither the participants or the study staff will know what drug (SBT115301 or placebo) is being given.

NCT ID: NCT05388851 Active, not recruiting - Melanoma Clinical Trials

Education for Prevention of Melanoma in Hispanic Populations

Start date: January 12, 2022
Phase: Phase 2
Study type: Interventional

This clinical trial is to develop an educational platform to educate and prevent melanoma in Hispanic populations. Melanoma is cancer arising in the skin. Educational platforms to increase the knowledge and practice of sun smart behaviors (sunscreen use, sun protective clothing use, self-skin examination) may help reduce risk of and incidence of melanoma and improve cancer survival.

NCT ID: NCT05388669 Active, not recruiting - Clinical trials for Advanced or Metastatic Non-small Cell Lung Cancer

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

PALOMA-3
Start date: August 5, 2022
Phase: Phase 3
Study type: Interventional

The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.

NCT ID: NCT05387876 Active, not recruiting - Colorectal Cancer Clinical Trials

Vitamin D Intervention and Associated Changes in the Gut Microbiome and Vitamin D Levels in Healthy Adults

VDMT
Start date: February 14, 2022
Phase: N/A
Study type: Interventional

Although dietary vitamin D supplementation has been used in the clinical setting for decades, the effect of supplementary vitamin D consumption on the structure of the microbiome has not been studied in humans in fine scale or with concomitant adjustment for dietary intake. Understanding the interaction of vitamin D with the microbiome in humans could lead to important advancements in the understanding of how vitamin D together with diet impacts the microbiome composition, and ultimately, risk of EOCRC. This study has the potential to lay the ground work for an adjunctive therapy to manipulate the microbiome to reduce risk of EOCRC. This proposed study is designed to evaluate the effect of vitamin D supplementation on the normal structure of the microbiome and data will not be used to diagnose, prevent, cure or treat disease.

NCT ID: NCT05387746 Active, not recruiting - Clinical trials for Burnout, Professional

Integrative Self-care Approaches for HCP Wellbeing

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this pilot study is to assess the impact of a hospital-based integrative self-care program (e.g., a. Reiki and b. Caring Science and Mindful Practice [CSMP] course) for interprofessional staff including nurses, physicians and/or medical residents, physical therapists, as well as other healthcare providers on their wellbeing.

NCT ID: NCT05387083 Active, not recruiting - Healthy Volunteer Clinical Trials

A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05

Start date: December 12, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2a, randomized, double-blind, proof-of-concept, single-center study evaluating the safety, tolerability, and whole blood concentration of TP-05 (lotilaner) in the killing of ticks after they have attached to human skin.

NCT ID: NCT05386680 Active, not recruiting - Clinical trials for Spinal Muscular Atrophy

Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam

STRENGTH
Start date: January 12, 2023
Phase: Phase 3
Study type: Interventional

This is an open-label, single arm, multi-center study. Approximately 28 participants aged 2 to <18 years will be enrolled stratified as 2 to 5 years and 6 to < 18 years. The study is comprised of 3 periods, Screening (up to 45 days), Treatment (1 day), and Follow-up (52 weeks).

NCT ID: NCT05386576 Active, not recruiting - Clinical trials for Acute Lymphoblastic Leukemia

A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Start date: June 16, 2022
Phase: Early Phase 1
Study type: Interventional

The researchers are doing this study to find out whether combining venetoclax with several different standard chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) in children is safe and effective in adults with newly diagnosed ALL. Participants in this study will be under the age of 60, and they will have T- or B-cell ALL.